Evidence map›Paper›PMID 32938758›Full record

ReviewOpen heart2020

Relationships between hyperinsulinaemia, magnesium, vitamin D, thrombosis and COVID-19: rationale for clinical management.

Isabella D Cooper, Catherine A P Crofts, James J DiNicolantonio, Aseem Malhotra, Bradley Elliott, Yvoni Kyriakidou, Kenneth H Brookler

Open access · goldAbstract readReview
In one paragraph

Review in Open heart, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 89 citations in OpenAlex.

  1. Trial
  2. Magnesium Level and Related Factors in Type 2 Diabetes Mellitus: A Cross-Sectional StudyEndocrine, metabolic & immune disorders drug targets · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Isabella D CooperSchool of Life Sciences, University of Westminster - Cavendish Campus, London, UK bellamitochondria@gmail.com.ORCID 0000-0001-7374-4340
Catherine A P CroftsSchool of Public Health and Interdisciplinary Studies, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand.ORCID 0000-0001-6109-8513
James J DiNicolantonioDepartment of Preventive Cardiology, Mid America Heart Institute, Kansas, Missouri, USA.ORCID 0000-0002-7888-1528
Aseem MalhotraVisiting professor of Evidence Based Medicine, Bahiana School of Medicine and Public Health, Salvador, Brazil.
Bradley ElliottSchool of Life Sciences, University of Westminster - Cavendish Campus, London, UK.ORCID 0000-0003-4295-3785
Yvoni KyriakidouSchool of Life Sciences, University of Westminster - Cavendish Campus, London, UK.ORCID 0000-0002-8883-2228
Kenneth H BrooklerAerospace Medicine and Vestibular Research Laboratory, Mayo Clinic Arizona, Scottsdale, Arizona, USA.ORCID 0000-0002-3088-9897
University of Westminster · GBAuckland University of Technology · NZEscola Bahiana de Medicina e Saúde Pública · BRMayo Clinic in Arizona · USMissouri Heart Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Risk factors for COVID-19 patients with poorer outcomes include pre-existing conditions: obesity, type 2 diabetes mellitus, cardiovascular disease (CVD), heart failure, hypertension, low oxygen saturation capacity, cancer, elevated: ferritin, C reactive protein (CRP) and D-dimer. A common denominator, hyperinsulinaemia, provides a plausible mechanism of action, underlying CVD, hypertension and strokes, all conditions typified with thrombi. The underlying science provides a theoretical management algorithm for the frontline practitioners.Vitamin D activation requires magnesium. Hyperinsulinaemia promotes: magnesium depletion via increased renal excretion, reduced intracellular levels, lowers vitamin D status via sequestration into adipocytes and hydroxylation activation inhibition. Hyperinsulinaemia mediates thrombi development via: fibrinolysis inhibition, anticoagulation production dysregulation, increasing reactive oxygen species, decreased antioxidant capacity via nicotinamide adenine dinucleotide depletion, haem oxidation and catabolism, producing carbon monoxide, increasing deep vein thrombosis risk and pulmonary emboli. Increased haem-synthesis demand upregulates carbon dioxide production, decreasing oxygen saturation capacity. Hyperinsulinaemia decreases cholesterol sulfurylation to cholesterol sulfate, as low vitamin D regulation due to magnesium depletion and/or vitamin D sequestration and/or diminished activation capacity decreases sulfotransferase enzyme SULT2B1b activity, consequently decreasing plasma membrane negative charge between red blood cells, platelets and endothelial cells, thus increasing agglutination and thrombosis.Patients with COVID-19 admitted with hyperglycaemia and/or hyperinsulinaemia should be placed on a restricted refined carbohydrate diet, with limited use of intravenous dextrose solutions. Degree/level of restriction is determined by serial testing of blood glucose, insulin and ketones. Supplemental magnesium, vitamin D and zinc should be administered. By implementing refined carbohydrate restriction, three primary risk factors, hyperinsulinaemia, hyperglycaemia and hypertension, that increase inflammation, coagulation and thrombosis risk are rapidly managed.

Indexed as

Dietary SupplementsDiet, Carbohydrate-RestrictedBetacoronavirusBiomarkersBlood GlucoseCoronavirus InfectionsCOVID-19Host-Pathogen InteractionsHumansHyperinsulinismInsulinKetonesMagnesiumPandemicsPneumonia, ViralPrognosisBiomarkersBlood GlucoseInsulinKetonesMagnesiumVitamin DZinccytokinesdeep vein thrombosisinflammationoxidative stressvenous thromboembol

Identifiers

PMID32938758
PMCPMC7496570
OpenAlexW3084753569

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.